Alphamab Oncology (HK:9966) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Alphamab Oncology has presented promising research updates on its innovative drug, JSKN033, at SITC 2024, highlighting its potential in treating advanced HER2-expressing solid tumors. The phase I/II clinical trial showed an 80% disease control rate, with a favorable safety profile among the participants. This advancement underscores Alphamab’s progress in developing cutting-edge cancer therapies, potentially boosting investor confidence in its stock.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.